Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC20512 VHL ligand 1 Featured
PROTAC-VHL-ligand is a von Hippel–Lindau (VHL) ligand used for the proteolysis targeting chimeras (PROTACs) method, induces target protein degradation..
More description
DC8456 Cardiogenol C (hydrochloride) Featured
Cardiogenol C is a diaminopyrimidine that induces cardiomyogenesis in mouse embryonic stem cells.
More description
DC10847 CAY10441(RO1138452) Featured
CAY10441 is a Selective prostacyclin IP receptor antagonist.
More description
DC10903 CAY10465 Featured
CAY10465 is an analog of resveratrol acting as a potent and selective aryl hydrocarbon receptor agonist, with a Ki of 0.2 nM.
More description
DC10579 CAY 10602 Featured
CAY10602 is a SIRT1 activator.
More description
DC4160 CB-03-01 Featured
CB-03-01 is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.
More description
DC10449 CB7921220 Featured
CB7921220 is an inhibitor of Adenylyl Cyclase isoform-1 (AC1) and isoform-6 (AC6).
More description
DC8497 CC-223 Featured
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM).
More description
DC7096 CC-401 Featured
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More description
DC11302 CCG215022 Featured
CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, GRK5 and GRK1, respectively.
More description
DC10005 CCT196969 Featured
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity.
More description
DC8324 CCT244747 Featured
CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies.
More description
DC10909 BN82002 Featured
CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties.
More description
DC12026 CDDO-2P-Imidazolide Featured
CDDO-2P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.
More description
DC12027 CDDO-3P-Imidazolide Featured
CDDO-3P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.
More description
DC12025 CDDO imidazolide Featured
CDDO-imidazolide is a potent inducer of heme oxygenase-1 and Nrf2/ARE signaling,with potent antiproliferative, differentiating, and anti-inflammatory activities.
More description
DC9277 C-DIM12 Featured
C-DIM12 is a novel synthetic activator of Nurr1.
More description
DC20334 CDK2 inhibitor 73 Featured
CDK2 inhibitor 73 is a potent, selective CDK2 inhibitor with IC50 of 44 nM for CDK2/cyclin A, displays 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM)..
More description
DC40786 (S,R,S)-AHPC-C6-NH2 hydrochloride Featured
(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized?E3 ligase ligand-linker conjugate?that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 hydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.
More description
DC48426 Rafutrombopag
Rafutrombopag is a thrombopoietin (TPO) agonist extracted from patent CN113929668 A.
More description
DC48425 TGFβR-IN-1
TGFβR-IN-1 is a long-acting tumor-activated prodrug of a TGFβR inhibitor.
More description
DC48423 Boc-NH-PEG11-OH
Boc-NH-PEG11-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
DC48422 6-Bnz-cAMP sodium salt
6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. 6-Bnz-cAMP selectively activates cAMP-dependent PKA but not Epac signaling pathways.
More description
DC48421 SHP2 protein degrader-1
SHP2 protein degrader-1 is a potent allosteric inhibitor of SHP2. SHP2 protein degrader-1 induces SHP2 degradation and cell apoptosis. SHP2 protein degrader-1 has the potential for the treatment of SHP2 related diseases.
More description
DC48420 Orexin B, rat, mouse TFA
Orexin B, rat, mouse (Rat orexin B) TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R. Orexin B, rat, mouse TFA stimulates food intake and energy expenditure and plays a significant role in sleep-wakefulness regulation.
More description
DC48419 MA242 free base
MA242 free base is a specific dual inhibitor of MDM2 and NFAT1. MA242 free base directly binds both MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated transcription of MDM2. MA242 free base induces apoptosis in pancreatic cancer cell lines regardless of p53 status.
More description
DC48417 IL-17A inhibitor 2
IL-17A inhibitor 2 is an IL-17A inhibitor for treating psoriasis, rheumatoid arthritis, and multiple sclerosis.
More description
DC48416 Brecanavir
Brecanavir (GW640385) is a novel, potent HIV protease inhibitor.
More description
DC48415 Pirmitegravir
Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties.
More description
DC48414 EZH2-IN-6
EZH2-IN-6 is an EZH2 inhibitor with enhanced antitumor activity.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X